Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
CONCLUSIONS: Pembrolizumab is not likely to be cost-effective in the treatment of PD-L1 positive, NSCLC for Chinese patients. Less aggressive pricing may increase accessibility for patients in China.
PMID: 30646794 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Economics | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology